biotech · Glanzmann Thrombasthenia · Von Willebrand Disease (VWD) · COAG
Hemab Therapeutics Holdings
Hemab Therapeutics Holdings is a biotech organization headquartered in frederiksberg, DK. It trades on NYSE under ticker COAG. Primary therapeutic focus areas include Glanzmann Thrombasthenia, Von Willebrand Disease (VWD
frederiksberg, DK HQ
2020 Founded
90 Employees
Public company Type
COAG · NYSE Ticker
Company details
- Status
- Public
- HQ
- frederiksberg, DK
- Founded
- 2020
- Employees
- 90
- Programs
- 4
- Drugs
- 0
- Patents
- 0
HMB-002 (Part A)
Phase 2 · small molecule · Von Willebrand Disease (VWD)
HMB-002 (Part A) for Von Willebrand Disease (VWD) is a Phase 2 program (small_molecule) at Hemab Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Internal code HMB-002-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hemab Therapeutics Holdings
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Von Willebrand Disease (VWD)
- Status
- active
- Trials
- 1